ICLR
ICON Public Limited Company
There isn't enough reported data to score ICLR yet.
ICLR Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Healthy | |
| Stable |
ICLR's revenue and cash flow are currently healthy, and its profitability and balance sheet are stable.
ICLR PE Valuation
ICLR has no meaningful PE right now: it lost money over the past year.
ICLR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Stable | |
| Stable | |
| Limited | |
| High |
Analysts expect ICLR's earnings, revenue and profitability to hold roughly steady.
ICLR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $11.26 | +288% |
| Q4 2025 | $2.90 | -70% |
| Q3 2025 | $7.39 | -18% |
| Q2 2025 | $9.72 | +13% |
| Q1 2025 | $9.18 | +11% |
| Q4 2024 | $9.53 | +29% |
| Q3 2024 | $8.99 | +45% |
| Q2 2024 | $8.60 | +39% |
| Q1 2024 | $8.24 | +33% |
ICLR earned $2.90 per share over the past year, down 70% from the year before.
ICLR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2B | -0.9% |
| Q2 2026 | $2.1B | +2.3% |
| Q1 2026 | $2B | +1.6% |
| Q4 2025 | $8.3B | +304% |
| Q3 2025 | $2B | +0.6% |
| Q2 2025 | $2B | -4.8% |
| Q1 2025 | $2B | -4.3% |
| Q4 2024 | $2B | -1.2% |
ICLR's revenue has picked up after three years of holding roughly level: $2B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 9.8% | +5.6 points |
| Q2 2026 | 6.7% | -3.7 points |
| Q1 2026 | 8.5% | -2.4 points |
| Q4 2025 | 5.4% | -9.2 points |
| Q3 2025 | 4.2% | -9.8 points |
| Q2 2025 | 10% | -0.5 points |
| Q1 2025 | 11% | -2.7 points |
| Q4 2024 | 15% | +1.7 points |
ICLR's operating margin was 9.8% last quarter, up 5.6 points from the same quarter a year ago.
ICLR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $307.1M | -8% |
| Q2 2026 | $238.8M | +110% |
| Q1 2026 | $136.2M | -43% |
| Q4 2025 | $862M | +211% |
| Q3 2025 | $333.9M | -7.1% |
| Q2 2025 | $113.9M | -38% |
| Q1 2025 | $239.3M | -20% |
| Q4 2024 | $277M | -28% |
ICLR generated $1.5B in free cash flow over the past year, up 60% from the year before.
ICLR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | 2.7x | Moderate |
| Q3 2025 | 2.0x | Moderate |
| Q2 2025 | 2.2x | Moderate |
| Q1 2025 | 2.0x | Healthy |
| Q4 2024 | 1.8x | Healthy |
| Q3 2024 | 1.7x | Healthy |
| Q2 2024 | 1.8x | Healthy |
| Q1 2024 | 1.9x | Healthy |
ICLR's net debt is about 2.7 years of its operating earnings (EBITDA), up from 1.8 years a year ago.
ICLR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 65.0 | Neutral |
| Stochastic | 79.3 | Neutral |
ICLR's weekly RSI is 65 (neutral) and its Stochastic is 79 (neutral).
ICLR PE vs Healthcare Sector
| Metric | ICLR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ICLR has no meaningful PE right now: it lost money over the past year.
ICLR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $183.8 | 9.1% above |
| 20 week MA | $173.9 | 15% above |
| 50 week MA | $152.9 | 31% above |
| 100 week MA | $161.8 | 24% above |
| 200 week MA | $213.5 | 6.1% below |
ICLR has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 6.1% below its 200-week average.
ICLR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $171.9 | $192.5 | +12% |
| 2021 | $192.5 | $307.9 | +60% |
| 2022 | $307.9 | $194.9 | -37% |
| 2023 | $194.9 | $283.1 | +45% |
| 2024 | $283.1 | $212.3 | -25% |
| 2025 | $212.3 | $182.8 | -14% |
| 2026 YTD | $182.8 | $200.5 | +9.7% |
ICLR has finished lower in three of the last six years. It's up 9.7% so far in 2026.